Results 111 to 120 of about 265 (150)

Miocamycin is an effective option in the treatment of various bacterial infections

Drugs & Therapy Perspectives, 2006
Miocamycin (midecamycin acetate), an oral macrolide, has a 16-membered ring and, in vitro, a similar or greater spectrum of activity to that of erythromycin. It is active against erythromycin-resistant staphylococcal and streptococcal species that express inducible-type resistance, has rapid and extensive penetration into body tissues and fluids, a low
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-5. Toxicity of metabolites of miocamycin: acute toxicity of Mb2 in rats.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin and is metabolized into 4 main metabolites. At previous study, LD0 values of Mb1 were estimated more than 5,000 mg/kg in male and female rats. The object of this study was to evaluate acute toxicity in male and female rats after single oral administration of Mb2, a metabolite of MOM.
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, H, Kawaoto, H, Watanabe, N, Ishiwatari, T, Koeda   +7 more
openaire   +1 more source

[The interference of miocamycin on the adhesiveness and coaggregation of the bacteria responsible for periodontopathies].

Minerva stomatologica, 1991
The authors studied the effect miocamycin has on the adherence and coaggregation of pathogenic bacteria in periodontopathy. The data obtained by optic microscopy, after treatment of the strains with doses of miocamycin equal to 1/4 and 1/8 of the MIC after 3 and 6 hours, shows the interference effect on the coaggregation and adhesivity of the ...
G, Chisari, L, Drago, A M, Lo Bue, M R, Gismondo   +3 more
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-8. Toxicity of metabolites of miocamycin: acute toxicity of Mb6 in rats.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. In the previous studies, we estimated LD50 values of Mb6 in male and female mice after single oral administration. The LD50 values were 4,150 mg/kg in male mice and 4,000 mg/kg in female mice, respectively.
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, H, Kawaoto, H, Watanabe, N, Ishiwatari, T, Koeda   +7 more
openaire   +1 more source

Clinical experience with miocamycin in the treatment of respiratory tract infections.

Drugs under experimental and clinical research, 1986
The object of the study was to evaluate the therapeutic effectiveness and tolerability of miocamycin, a new macrolide antibiotic, in 86 patients with lower respiratory tract infections. The mean peak concentration of miocamycin was determined in bronchial secretions. High concentrations were recorded, in some cases exceeding serum levels. The pathogens
R, Rimoldi, M, Fioretti, M, Bandera
openaire   +1 more source

[Miocamycin in the prevention and treatment of cutaneous infections in the emergency service].

Minerva medica, 1988
The efficacy and tolerability of a new macrolide, Myocamycine, were assessed in the anti-infectious prophylaxis of lacerations and contusions and in the treatment of already infected wounds or phlegmons. A total of 175 patients were treated. Side effects induced the suspension of treatment in 8% of cases while the drug proved effective in preventing ...
G, Bertinieri, L, Caser, G, Ceffa, P, Cortese, C, Martina, G, Riccardi, G, Calogero   +6 more
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-1. Toxicity of metabolites of miocamycin: acute toxicity of Mb1 in mice.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. MOM is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. The object of this study was to evaluate acute toxicity in male and female mice after single oral administration of Mb1, a metabolite of MOM, at a dose
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, H, Kawaoto, T, Itoh, T, Koeda   +6 more
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-7. Toxicity of metabolites of miocamycin: acute toxicity of Mb6 in mice.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin and is metabolized into 4 main metabolites. In the present studies, we evaluated acute toxicity and estimated LD50 values of Mb6, one of the main metabolites of MOM, in male and female mice after single oral administration. Observations were continued for 1 week after treatment.
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, H, Kawaoto, T, Itoh, T, Koeda   +6 more
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-3. Toxicity of metabolites of miocamycin: subacute toxicity of Mb1 in rats.

The Japanese journal of antibiotics, 1985
Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. In the previous study, LD0 values of Mb1 were estimated more than 5,000 mg/kg in male and female rats as Mb1 did not exhibited any lethal toxicity even at the maximum physically applicable dose of 5,000 mg/kg ...
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, T, Niizato, H, Kawaoto, H, Watanabe, N, Ishiwatari, H, Hayasaka, T, Koeda   +9 more
openaire   +1 more source

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-2. Toxicity of metabolites of miocamycin: acute toxicity of Mb1 in rats.

The Japanese journal of antibiotics, 1985
Acute toxicity studies on miocamycin (MOM), non-crystalline solid, and its metabolite Mb1 were performed in mice in the previous studies. In the present studies, we evaluated acute toxicity of Mb1 in male and female rats after single oral administration at the maximum physically applicable dose of 5,000 mg/kg.
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, H, Kawaoto, H, Watanabe, N, Ishiwatari, T, Koeda   +7 more
openaire   +1 more source